MedPath

The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

Phase 2
Completed
Conditions
Cytomegalovirus Retinitis
HIV Infections
Registration Number
NCT00002356
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Brief Summary

To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwise ineligible for ISIS Pharmaceuticals' controlled trials OR who have failed ISIS 2922 therapy on another controlled clinical trial.

PER 2/8/96 AMENDMENT: Patients must rollover from another ISIS 2922 controlled trial.

Detailed Description

Patients receive intravitreal injections of ISIS 2922 at doses of either 150 or 300 mcg, depending on CMV retinitis location and extent of retinal involvement. There is a 3-week Induction period followed by at least 18 weeks of Maintenance. Induction is given on days 1, 8, and 15, and Maintenance doses are given every 14 days, beginning on day 29.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (25)

UCI College of Medicine

🇺🇸

Irvine, California, United States

Emory Univ School of Medicine / Emory Eye Ctr

🇺🇸

Atlanta, Georgia, United States

Hahnemann Univ Hosp

🇺🇸

Philadelphia, Pennsylvania, United States

Univ of Texas Southwestern Med Ctr of Dallas

🇺🇸

Dallas, Texas, United States

Charlotte Eye Ear Nose & Throat Association

🇺🇸

Charlotte, North Carolina, United States

Virginia Eye Consultants

🇺🇸

Norfolk, Virginia, United States

Community Eye Med Group

🇺🇸

Pasadena, California, United States

Retina - Vitreous Associates Med Group

🇺🇸

Los Angeles, California, United States

Santa Clara Valley Med Ctr

🇺🇸

San Jose, California, United States

Dr Julio Perez

🇺🇸

Fort Lauderdale, Florida, United States

Georgia Retina

🇺🇸

Atlanta, Georgia, United States

Univ of Illinois

🇺🇸

Chicago, Illinois, United States

Dr Alan Palestine

🇺🇸

Washington, District of Columbia, United States

Vitreo - Retinal Consultants

🇺🇸

New York, New York, United States

Graduate Hosp

🇺🇸

Philadelphia, Pennsylvania, United States

Vitreoretinal Consultants

🇺🇸

Houston, Texas, United States

Novum Inc

🇺🇸

Seattle, Washington, United States

San Diego Naval Hosp

🇺🇸

San Diego, California, United States

Univ of Colorado Health Sciences Ctr

🇺🇸

Denver, Colorado, United States

Duke Univ

🇺🇸

Durham, North Carolina, United States

Bascon Palmer Eye Institute

🇺🇸

Miami, Florida, United States

Indiana Univ Med Ctr

🇺🇸

Indianapolis, Indiana, United States

Tulane Univ

🇺🇸

New Orleans, Louisiana, United States

Univ of California San Francisco / SF Gen Hosp

🇺🇸

San Francisco, California, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath